



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

EGF AND PDGF RECEPTORS IN ENDOMETRIAL CANCER

GREGORY KEITH DAVIS

A thesis submitted to fulfill the requirements for the degree of
Doctor of Medicine, University of Auckland, 1993.

ABSTRACT

Despite its relatively good long term survival compared to other cancers in the female, endometrial carcinoma still kills 20% of those women who develop the disease worldwide. Abnormalities in growth factor receptors have been shown to be important in both the prognosis and probably the malignant transformation of the two other oestrogen-dependent cancers, breast and ovary, which suggests that similar defects may occur in endometrial cancer.

In this thesis, two of these growth factor receptors, those for the epidermal and platelet-derived growth factors, are studied in endometrial cancer at the levels of the gene and expression of the proteins on the cell surface, in an attempt to detect abnormalities which might be implicated in carcinogenesis.

No amplification or rearrangement of the EGFR gene was detected on 13 tumour samples initially, or of the EGF, PDGF α - and β -subunit receptor genes subsequently on a mixture of tumour samples and cell from endometrial cancer cell lines.

The size of the EGF and PDGF receptor proteins and the activation of their tyrosine kinase domains was assessed in an oestrogen responsive (Ishikawa) and an oestrogen independent (HEC-1-A) endometrial cancer cell line. Functioning receptors for EGF were demonstrated in both cell lines but no PDGF receptors were detected. EGF-binding studies were carried out and appropriate affinity constants and receptor numbers obtained in both cell lines.

The growth of Ishikawa and HEC-1-A cells in culture was studied but because of the rapid growth of both lines in the absence of serum no meaningful mitogenic effects were shown by any growth factor or steroid.

Phorbol ester and TGF- β inhibited the growth of HEC-1-A and Ishikawa cells, respectively. Of particular interest was that, despite the reported sensitivity of Ishikawa cells to oestrogen, no consistent stimulation was observed.

The growth of both cell lines in the absence of serum suggested that the cells might be secreting growth factors and conditioned medium was obtained from long term, large scale cultures. The medium was concentrated and passed through a size exclusion column and the fractions assayed for DNA synthesis and competition for EGF-binding to Swiss 3T3 cells. No consistent effect on either of these assays was shown and no further investigation was undertaken.

ACKNOWLEDGEMENTS

I would like to thank Professor Michael Chapman, Guy's Hospital, London, who made it possible, and Drs Michael Fry and George Panayotou of the Ludwig Institute for Cancer Research (Middlesex Hospital/ University College Branch), London, who tried to make me do it properly. The bulk of the work on which this thesis is based was carried out at the LICR and I acknowledge the support of the LICR and the Director, Professor Michael Waterfield.

TABLE OF CONTENTS

1	Introduction	1
1.1	Endometrial carcinoma	1
1.2	Carcinogenesis	13
1.3	Growth factors	20
1.4	Growth factor receptors	25
1.5	Growth factors as transforming proteins	36
1.6	Proto-oncogenes in human cancers	44
1.7	Growth factor receptors in normal endometrium	51
1.8	Proto-oncogenes in endometrial cancer	53
1.9	Summary	56
2	Methods	58
2.1	Cell culture	58
2.2	Binding assays	63
2.3	SDS-polyacrylamide gel electrophoresis	65
2.4	Western blotting of proteins	68
2.5	Kinase assays	69
2.6	Concentration of conditioned medium	74
2.7	DNA synthesis assay	74
2.8	Column chromatography	76
2.9	DNA methods	77
3	Is there amplification or rearrangement of growth factor receptor genes in endometrial cancer?	88
3.1	Introduction	88
	Study using tumour samples	90
3.2	Sample analysis and results	90
3.3	Discussion	93
	Study using tumour samples and cell lines	98
3.4	Sample analysis and results	98
3.5	Discussion	102

4	Do endometrial cancer cell lines possess functional EGF and PDGF receptors?	115
4.1	Introduction	115
4.2	Assays of tyrosine phosphorylation	116
4.3	Binding studies	119
4.4	Discussion	122
4.5	Summary	127
5	The regulation of growth of endometrial cancer cell lines in culture	134
5.1	Introduction	134
5.2	Materials and methods	138
5.3	Results	142
5.4	Discussion	147
6	Do endometrial cancer cell lines in culture secrete growth factors?	159
6.1	Introduction	159
6.2	Materials and methods	161
6.3	Results	164
6.4	Discussion	166
7	General discussion	176
	Bibliography	182

LIST OF FIGURES AND TABLES

Fig 1.1	Schematic representation of protein-tyrosine kinase receptor subclasses	26
Fig 1.2	Proposed structure-function topology of the EGFR	27
Fig 1.3	Substrates of receptor tyrosine kinases	34
Table 3.1	List of endometrial samples from which DNA was obtained	106
Table 3.2	Densitometry ratios for cDNA probes to EGFR and <i>c-erbB-2</i> genes	107
Fig 3.1	ENDO 1	108
Fig 3.2	ENDO 2	109
Fig 3.3	EGFR	110
Fig 3.4	PDGF- α R	111
Fig 3.5	PDGF- β R	112
Fig 3.6	<i>c-fms</i> /CSF-1R (neoplastic endometrium)	113
Fig 3.7	<i>c-fms</i> /CSF-1R (normal endometrium)	114
Fig 4.1	Immunoprecipitation of the EGFR from Ishikawa and HEC-1-A cells	128
Fig 4.2	Protein tyrosine kinase activity in Ishikawa cells using antiphosphotyrosine antibodies	129
Fig 4.3	Effect of growth factors and steroids on protein tyrosine kinase activity in Ishikawa and HEC-1-A cells	130
Fig 4.4	Binding of 125 I-EGF to Ishikawa cells	131
Fig 4.5	Binding of 125 I-EGF to HEC-1-A cells	132
Fig 4.6	Effect of growth factors and steroids on binding of 125 I-EGF to Ishikawa cells	133

Fig 5.1	Growth of cells in increasing concentrations of DC-FCS	151
Fig 5.2	Growth of cells in oestradiol and increasing concentrations of DC-FCS	152
Fig 5.3	Growth of cells plated at low and high density	153
Fig 5.4	Effect of various agents on growth of HEC-1-A cells	154
Fig 5.5	Effect of various agents on growth of Ishikawa cells	155
Fig 5.6	Growth of Ishikawa cells in different concentrations of DC-FCS and oestradiol	156
Fig 5.7	Growth of Ishikawa cells in different concentrations of tamoxifen and R5020	157
Fig 5.8	Growth of Ishikawa cells in different concentrations of RU486 and ICI 168,384	158
Fig 6.1	Growth of cells on cytodex beads	170
Fig 6.2	UV absorbance profiles for conditioned medium and molecular weight standards	171
Fig 6.3	A,B. Effect of column fractions on DNA synthesis	172
	C,D. Effect of serum and ¹²⁵ I-EGF binding	173
Fig 6.4	UV absorbance profile and effect on DNA synthesis, second column run	174
Fig 6.5	Effect of conditioned medium on PTK activity	175

LIST OF ABBREVIATIONS

A_{280}	absorbance at 280 nm
α TPA	alpha form of TPA
APC	adenomatous polyposis coli gene
APS	ammonium persulphate
bFGF	basic FGF
BES	N,N-bis(2-Hydroxyethyl)-2-aminoethanesulfonic acid
BSA	bovine serum albumin
cAMP	cyclic adenosine monophosphate
CCM	concentrated, conditioned medium
cDNA	complementary DNA
cm	centimetre
CM	conditioned medium
cpm	counts per minute
CSF	colony stimulating factor
CSF-1	colony stimulating factor-1
CSF-1R	colony stimulating factor-1 receptor
DAG	1,2-diacylglycerol
dATP	deoxyadenosine triphosphate
DC	direct current; dextran:charcoal
DCC	deleted in colon cancer gene
DC-FCS	dextran:charcoal-stripped FCS
dCTP	deoxycytidine triphosphate
dGTP	deoxyguanosine triphosphate
DMEM	Dulbecco's modified Eagle's medium
DNA	deoxyribonucleic acid
dNTPs	deoxynucleotide triphosphates
DTT	dithiothreitol
dTTP	deoxythymidine triphosphate
EDTA	ethylenediamine tetra-acetic acid
EGF	epidermal growth factor
EGFR	epidermal growth factor receptor
ER	oestrogen receptor
FAP	familial adenomatous polyposis
FCS	foetal calf serum
FGF	fibroblast growth factor

FIGO	International Federation of Gynaecologists and Obstetricians
FPLC™	fast protein liquid chromatography
g	gram
G1,2,3	grade 1,2,3; first growth phase of cell cycle
GAP	GTPase activating protein
GFR	growth factor receptor
GDP	guanosine diphosphate
GTP	guanosine triphosphate
h	hour
HCl	hydrochloric acid
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
ICI 164,384	N-n-butyl-11-3,17β-dihydroxyoestra-1,3,5(10)-trien- 7α-yl-N-methylundecamide
¹²⁵ I-EGF	¹²⁵ I-labelled EGF
IGF-1	insulin-like growth factor-1
IGF-1R	insulin-like growth factor-1 receptor
IL-3	interleukin-3
IP ₃	1,4,5-triphosphate
kb	kilobase
kD	kilodalton
l	litre
LICR	Ludwig Institute for Cancer Research
LOH	loss of heterozygosity
M	mole, molar
MCC	mutated in colon cancer gene
μg	microgram
μl	microlitre
mg	milligram
min	minute
ml	millilitre
mM	millimolar
mRNA	messenger RNA
MW	molecular weight
ng	nanogram
nM	nanomolar
NRK	normal rat kidney

NR6 ⁺	subclone of Swiss 3T3 cells with transfected EGFR
OCs	oral contraceptives
OD	optical density
4-OHtam	trans 4-hydroxytamoxifen
O-2A	oligodendrocyte-type 2 astrocyte
p	short arm of chromosome
PBS	phosphate-buffered saline
PDGF	platelet-derived growth factor
PDGF- α R	PDGF alpha receptor subunit
PDGF- β R	PDGF beta receptor subunit
PDGFR	PDGF receptor
pg	picogram
PI	phosphatidylinositide
PI3-K	phosphatidylinositol 3'-kinase
PKC	protein kinase C
PLC- γ	phospholipase C- γ
pM	picomolar
PMSF	phenylmethylsulfonyl fluoride
PR	progesterone receptor
PTK	protein-tyrosine kinase
q	long arm of chromosome
R5020	promegestone
RB	retinoblastoma (gene/protein)
RFLP	restriction fragment length polymorphism
RNA	ribonucleic acid
rpm	revolutions per minute
RPMI	Roswell Park Memorial Institute
RR	relative risk
RU486	17 β -hydroxy-11 β -(4-dimethylamino-phenyl)-17 α -(1-propynyl)-estra-4,9-dien-3-one
SDS	sodium dodecyl sulphate
SDS-PAGE	SDS-polyacrylamide gel electrophoresis
SEM	standard error of mean
SSC	standard saline citrate
SSV	simian sarcoma virus
TAE	tris-acetate EDTA
TE	tris-EDTA

TEMED	N,N,N',N'-tetramethylethylenediamine
TGF- α	transforming growth factor- α
TGF- β	transforming growth factor- β
tris	tris(hydroxymethyl) amino methane
TPA	phorbol 12-tetradecanoate 13-acetate
UV	ultraviolet
<i>v-<i>onc</i></i>	viral oncogene
v/v	volume for volume
WT1	Wilms tumour gene
w/v	weight for volume